ImCheck

About ImCheck Therapeutics

Bringing a novel class of checkpoints modulators into the clinic leveraging γδ T cells activation
ImCheck

About ImCheck

ImCheck Therapeutics is designing and developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules and engage a specific type of immune cells, γ9δ2 T cells.

ImCheck has developed a broad pipeline of monoclonal antibody (mAB) drug candidates targeting BTNs with its lead program entering clinical evaluation in 2020. Due to their mechanism of action, including the ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class" mAbs may be able to improve upon the first-generation of checkpoint inhibitors in cancer. ImCheck’s programs also have potential in autoimmune indications, which the company is currently investigating.

Starting in 2020, the company's first drug candidate, an anti-BTN3 antibody, is expected to begin phase I assessment in oncology.

Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a world-renowed researcher in γδT cells and butyrophilins, from the experience of an expert management team and from the commitment of leading life science-focused investors. 

---

ImCheck’s translational research platform, where the company conducts its discovery and development research for a new generation therapeutic antibodies, has been financially supported by the European Union through its European Regional Development Fund.

The amount granted was: €717,000

Leadership Team

Pierre d'EPENOUX
Pierre d'EPENOUXChief Executive Officer

René HOET
René HOETPhD
Chief Scientific Officer
Paul FROHNA
Paul FROHNAMD, PhD, PharmD
Chief Medical Officer

Board Members

Debasish ROYCHOWDHURY
Debasish ROYCHOWDHURYMD
Independent Chairman
Thibaut ROULON
Thibaut ROULONPhD
Bpifrance
Michael BARAN
Michael BARANPhD, MBA
Pfizer Ventures
Regina HODITS
Regina HODITSPhD, MBA
Wellington Partners Life Sciences
Rémi DROLLER
Rémi DROLLERPhD
Kurma Partners France
Detlev MENNERICH
Detlev MENNERICHPhD
Boehringer Ingelheim Venture Fund
Vincent BRICHARD
Vincent BRICHARDMD, PhD
Life Sciences Partners
Bram VANPARYS
Bram VANPARYSPhD, MBA
Gimv
Pierre d'EPENOUX
Pierre d'EPENOUXChief Executive Officer

Board observers

Geeta VEMURI
Geeta VEMURIPhD, MBA
Agent Capital
Jenna FOGER
Jenna FOGERAlexandria Venture Investments

Company Founders

Daniel OLIVE
Daniel OLIVEMD, PhD
Scientific Founder
Alem TRUNEH
Alem TRUNEHPhD
Scientific Advisor
Benjamin CHARLES
Benjamin CHARLESPharmD, MBA
------

Investors

 
Bpifrance
Pfizer
Wellington Partners
Agent Capital
 Alexandria Venture Investments
 
Boehringer Ingelheim
Kurma Partners
IDinvest Partners
GIMV
LSP
The next game-changer in immuno-oncology

Pierre d'EPENOUX

Chief Executive Officer

The next game-changer in immuno-oncology

ImCheck’s first clinical trial starting next year with ICT01 is based on comprehensive translational research supporting its potential to activate γδ T cells to kill malignant cells. The Series B funding, bringing the total capital raised in 2.5 years to nearly $80 million, allows us to accelerate the development of our unique immuno-oncology pipeline, further investigate the potential of our antibodies in autoimmune disease, and establish clinical operations and corporate development activities in the US.